Global Acute Conjunctivitis Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 211 pages | ID: G4206B263F8EN
Precision Business Insights (PBI)

Abstracts

Acute Conjunctivitis Treatment Market

Conjunctivitis, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Conjunctivitis can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Symptoms includes tearing, itching and redness of the eyes. It can also lead to discharge or crusting around the eyes. It’s important to stop wearing contact lenses whilst affected by conjunctivitis. Conjunctivitis often resolves on its own, but treatment can speed up the recovery process. Allergic conjunctivitis can be treated with antihistamines. Bacterial conjunctivitis can be treated with antibiotic eye drops.

Acute conjunctivitis treatment market is because of increasing aging of the population, increase in ophthalmic diseases prevalence rate, rise in investments for the development of new products, growing conscious towards health, funded eye check-up campaigns by governments of different countries are driving the growth of acute conjunctivitis treatment market. Moreover, increasing awareness about various eye infections and rise in blindness prevalence among geriatric population boosting the market growth of acute conjunctivitis treatment. However, due to the stringent regulations in drugs developmental process and side effects associated with the various antibiotics would hamper the adoption of eye infection pharmaceutical treatment, in turn, hinder the market growth.

Acute conjunctivitis treatment market is segmented on the basis of type, dosage form, drug class, distribution channel, and geography

Based on the type, acute conjunctivitis treatment market is segmented as:

• Viral Conjunctivitis
• Bacterial Conjunctivitis
• Allergic Conjunctivitis
• Conjunctivitis Caused by Irritants

Based on dosage form, acute conjunctivitis treatment market is segmented as:

• Gels and Cream
• Eye drops
• Tablets and Capsules

Based on the drug class, acute conjunctivitis treatment market is segmented as:

• Antihistamines
• Antibiotic
• Mast cell stabilizers
• Anti-inflammatory drugs
• Others

Based on distribution channel, acute conjunctivitis treatment market is segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

As per the clinical study conducted by scientists Neal P. Barney and Amir A. Azari in 2013, which was published in Journal of American Medical Association (JAMA), states that bacterial conjunctivitis accounts for about 50% of conjunctivitis cases in U.S. and also estimated that the bacterial conjunctivitis incidence rate was anticipated as 135 in 10,000.Top pharma companies are dominating the market owing to different factors like sale, strong global presence, and efficient distribution network, R&D investments, products of superior quality, and strong brand image. In 2016, Irish based pharma company Shire’s Xiidra received U.S.FDA approval which is used to treat dry-eye. In 2015, Bausch & Lomb Inc. acquired Doctor’s Allergy Formula in order to expand its ophthalmic product portfolio,

On the basis of geographical regions, acute conjunctivitis market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is dominating global acute conjunctivitis market owing to few factors like rising more number of approvals by FDA, various strong strategies by pharma companies, rise in R&D investments. The European market is the second largest market for acute conjunctivitis treatment. Increase in prevalence and growing awareness of conjunctivitis and its treatments are leading the growth of Asia Pacific acute conjunctivitis treatment market. The Middle East and Africa acute conjunctivitis treatment market is expected to have limited growth because of lack of traditional healthcare practices and slow adoption of new products and therapies.

Some of the players in global acute conjunctivitis treatment market are Pfizer, Inc. (U.S), Allergan Inc. (Ireland), Boehringer Ingelheim GmbH (Germany), CIBA Vision Ophthalmics (U.S), Sanofi (France), Novartis AG (Switzerland), Bausch & Lomb Inc. (Valeant) (Canada), Merck & Co., Inc. (U.S), and Santen Pharmaceuticals Co. Ltd.(Japan)

In June 2017, Teva Pharmaceuticals launched, generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2%, in U.S used to treat Allergic conjunctivitis

In February 2015, Novartis division, Alcon has received USFDA approval for Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, to treat ocular itching which is associated with allergic conjunctivitis

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET INTRODUCTION

2.1. Global Acute Conjunctivitis Treatment Market – Taxonomy
2.2. Global Acute Conjunctivitis Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Type
  2.2.3. Dosage Form
  2.2.4. Distribution Channel

3. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Acute Conjunctivitis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Acute Conjunctivitis Treatment Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Acute Conjunctivitis Treatment Market – Product Innovations

4. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Antihistamines
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Antibiotic
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Mast cell stabilizers
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis
5.4. Anti-inflammatory drugs
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.4.3. Market Opportunity Analysis
5.5. Others
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.5.3. Market Opportunity Analysis

6. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET FORECAST, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Viral Conjunctivitis
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Bacterial Conjunctivitis
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Allergic Conjunctivitis
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis
6.4. Conjunctivitis Caused by Irritants
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.4.3. Market Opportunity Analysis

7. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET FORECAST, BY DOSAGE FORM, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Gels and Cream
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Eye Drops
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Tablets and Capsules
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis

8. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Retail Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Hospital Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis

9. GLOBAL ACUTE CONJUNCTIVITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.5.3. Market Opportunity Analysis
9.6. Global Acute Conjunctivitis Treatment Market - Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2017 – 2023

10. NORTH AMERICA ACUTE CONJUNCTIVITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Antihistamines
  10.1.2. Antibiotic
  10.1.3. Mast cell stabilizers
  10.1.4. Anti-inflammatory drugs
  10.1.5. Others
10.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Viral Conjunctivitis
  10.2.2. Bacterial Conjunctivitis
  10.2.3. Allergic Conjunctivitis
  10.2.4. Conjunctivitis Caused by Irritants
10.3. Dosage Form Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Gels and Cream
  10.3.2. Eye drops
  10.3.3. Tablets and Capsules
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Retail Pharmacies
  10.4.2. Hospital Pharmacies
  10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.5.1. U.S.
  10.5.2. Canada
10.6. North America Acute Conjunctivitis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Type, Dosage Form, and Country, 2017 – 2023
10.7. North America Acute Conjunctivitis Treatment Market Dynamics – Trends

11. EUROPE ACUTE CONJUNCTIVITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Antihistamines
  11.1.2. Antibiotic
  11.1.3. Mast cell stabilizers
  11.1.4. Anti-inflammatory drugs
  11.1.5. Others
11.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Viral Conjunctivitis
  11.2.2. Bacterial Conjunctivitis
  11.2.3. Allergic Conjunctivitis
  11.2.4. Conjunctivitis Caused by Irritants
11.3. Dosage Form Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Gels and Cream
  11.3.2. Eye drops
  11.3.3. Tablets and Capsules
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Retail Pharmacies
  11.4.2. Hospital Pharmacies
  11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.5.1. Germany
  11.5.2. UK
  11.5.3. France
  11.5.4. Spain
  11.5.5. Italy
  11.5.6. Russia
  11.5.7. Poland
  11.5.8. Rest of Europe
11.6. Europe Acute Conjunctivitis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Type, Dosage Form, Distribution Channel and Country, 2017 – 2023
11.7. Europe Acute Conjunctivitis Treatment Market Dynamics – Trends

12. ASIA-PACIFIC ACUTE CONJUNCTIVITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Antihistamines
  12.1.2. Antibiotic
  12.1.3. Mast cell stabilizers
  12.1.4. Anti-inflammatory drugs
  12.1.5. Others
12.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Viral Conjunctivitis
  12.2.2. Bacterial Conjunctivitis
  12.2.3. Allergic Conjunctivitis
  12.2.4. Conjunctivitis Caused by Irritants
12.3. Dosage Form Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Gels and Cream
  12.3.2. Eye drops
  12.3.3. Tablets and Capsules
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Retail Pharmacies
  12.4.2. Hospital Pharmacies
  12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  12.5.1. Japan
  12.5.2. China
  12.5.3. India
  12.5.4. ASEAN
  12.5.5. Australia & New Zealand
  12.5.6. Rest of Asia-Pacific
  12.5.7. Asia-Pacific Acute Conjunctivitis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Type, Dosage Form, Distribution Channel and Country, 2017 – 2023
  12.5.8. Europe Acute Conjunctivitis Treatment Market Dynamics – Trends

13. LATIN AMERICA ACUTE CONJUNCTIVITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Antihistamines
  13.1.2. Antibiotic
  13.1.3. Mast cell stabilizers
  13.1.4. Anti-inflammatory drugs
  13.1.5. Others
13.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Viral Conjunctivitis
  13.2.2. Bacterial Conjunctivitis
  13.2.3. Allergic Conjunctivitis
  13.2.4. Conjunctivitis Caused by Irritants
13.3. Dosage Form Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Gels and Cream
  13.3.2. Eye drops
  13.3.3. Tablets and Capsules
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Retail Pharmacies
  13.4.2. Hospital Pharmacies
  13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.5.1. Brazil
  13.5.2. Mexico
  13.5.3. Argentina
  13.5.4. Venezuela
  13.5.5. Rest of Latin America
13.6. Latin America Acute Conjunctivitis Treatment Market - Opportunity Analysis Index, By Drug Analysis, Type, Dosage Form, Distribution Channel and Country, 2017 – 2023
13.7. Latin America Acute Conjunctivitis Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA ACUTE CONJUNCTIVITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.1.1. Antihistamines
  14.1.2. Antibiotic
  14.1.3. Mast cell stabilizers
  14.1.4. Anti-inflammatory drugs
  14.1.5. Others
14.2. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.2.1. Viral Conjunctivitis
  14.2.2. Bacterial Conjunctivitis
  14.2.3. Allergic Conjunctivitis
  14.2.4. Conjunctivitis Caused by Irritants
14.3. Dosage Form Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.3.1. Gels and Cream
  14.3.2. Eye drops
  14.3.3. Tablets and Capsules
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.4.1. Retail Pharmacies
  14.4.2. Hospital Pharmacies
  14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.5.1. Gulf Cooperation Council (GCC) Countries
  14.5.2. Israel
  14.5.3. South Africa
  14.5.4. Rest of MEA
14.6. MEA Acute Conjunctivitis Treatment Market - Opportunity Analysis Index By Drug Analysis, Type, Dosage Form, Distribution Channel and Country, 2017 – 2023
14.7. MEA Acute Conjunctivitis Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Pfizer, Inc. (U.S)
  15.2.2. Allergan Inc. (Ireland)
  15.2.3. Boehringer Ingelheim GmbH (Germany)
  15.2.4. CIBA Vision Ophthalmics (U.S)
  15.2.5. Sanofi (France)
  15.2.6. Novartis AG (Switzerland)
  15.2.7. Bausch & Lomb Inc. (Valeant) (Canada)
  15.2.8. Merck & Co., Inc. (U.S)
  15.2.9. Santen Pharmaceuticals Co. Ltd.(Japan)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONY